Valuation: Qiagen NV

Market Cap 8.51B 7.44B 6.86B 6.33B 11.92B 820B 12.19B 82.02B 32.26B 401B 31.96B 31.26B 1,382B P/E 2026 *
19.2x
P/E 2027 * 18.7x
Enterprise Value 9.14B 7.99B 7.37B 6.8B 12.81B 881B 13.1B 88.15B 34.67B 431B 34.34B 33.59B 1,485B EV / Sales 2026 *
4.26x
EV / Sales 2027 * 3.9x
Free-Float
99.27%
Yield 2026 *
-
Yield 2027 * 0.46%
Manager TitleAgeSince
Chief Executive Officer 61 2019-10-06
Director of Finance/CFO 58 2003-12-31
Chief Operating Officer - 2022-03-31
Director TitleAgeSince
Director/Board Member 77 2011-05-31
Director/Board Member 60 2021-01-07
Director/Board Member 72 2022-06-22
Change 5-day change 1-year change 3-year change Capi.($)
-2.28%-4.05% - - 8.58B
+3.90%-0.39%+376.72%+599.59% 38.09B
-1.70%+4.46%+7.46%+57.67% 35.29B
-2.01%-0.76%+26.35%-6.83% 35.13B
+0.06%+0.34%+2.32%+29.30% 27.22B
+0.46%-3.49% - - 16.14B
-0.04%-0.09%+68.48%+117.39% 15.36B
+1.12%+1.91%+15.90%+19.65% 13.89B
0.00%+1.36%+15.74%-30.62% 13.02B
-0.08%-3.01%+1,271.69%+649.69% 11.76B
Average -0.06%-0.61%+223.08%+179.48% 22.88B
Weighted average by Cap. +0.10%-0.71%+168.84%+183.13%

Financials

2026 *2027 *
Net sales 2.15B 1.87B 1.73B 1.59B 3.01B 207B 3.07B 20.68B 8.13B 101B 8.06B 7.88B 348B 2.26B 1.97B 1.82B 1.68B 3.17B 218B 3.24B 21.77B 8.56B 107B 8.48B 8.3B 367B
Net income 415M 363M 335M 308M 581M 39.95B 594M 4B 1.57B 19.57B 1.56B 1.52B 67.36B 473M 414M 382M 352M 663M 45.6B 678M 4.56B 1.79B 22.33B 1.78B 1.74B 76.87B
Net Debt 635M 555M 512M 472M 890M 61.17B 910M 6.12B 2.41B 29.96B 2.39B 2.33B 103B 293M 256M 237M 218M 411M 28.24B 420M 2.83B 1.11B 13.83B 1.1B 1.08B 47.62B
Logo Qiagen NV
Qiagen NV is a holding company based in the Netherlands. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The Company's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-